TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27569033

Group type: EXPERIMENTAL
Intervention: Z-lengthening of the transverse carpal ligament (TCL) according to a modified Simonetta technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Complete release of the transverse carpal ligament (TCL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both interventions (Z-lengthening and complete release)
Number of subjects: 80
Study: 24907721

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 62
Study: 22037389

Group type: EXPERIMENTAL
Intervention: DNR order
Number of subjects: 375

Group type: COMPARATOR
Intervention: Full Code order
Number of subjects: 375
Study: 20356687

Group type: EXPERIMENTAL
Intervention: Early salvage hormonal therapy (HT) initiated with PSA < 10 ng/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late salvage hormonal therapy (HT) initiated with PSA ≥ 10 ng/mL
Number of subjects: 0
Study: 17942524

Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta) treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (untreated MS patients)
Number of subjects: 56
Study: 19742086

Group type: EXPERIMENTAL
Intervention: 5% lidocaine and 5% prilocaine cream (Emla Astra)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50% diluted Citanest solution with ring-type infiltration
Number of subjects: 0
Study: 15804789

Group type: EXPERIMENTAL
Intervention: Swimming (water therapy)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Bathing (control)
Number of subjects: 377
Study: 12127196

Group type: EXPERIMENTAL
Intervention: Pretreatment abstainers
Number of subjects: 142

Group type: COMPARATOR
Intervention: Non-abstainers
Number of subjects: 142
Study: 9129588

Group type: EXPERIMENTAL
Intervention: Clarithromycin plus lansoprazole
Number of subjects: 104

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 104
Study: 8188164

Group type: EXPERIMENTAL
Intervention: Optimal conditions for serum specimen preparation (immediate centrifugation after clot formation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Centrifugation through a paraffin plug (serum separator tube)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three freeze-thaw cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative branched DNA signal amplification assay under optimal conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluctuations in hepatitis C virus RNA levels
Number of subjects: 0
Study: 3683478

Group type: COMPARATOR
Intervention: Bilateral myringotomy (Group 1)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Placement of tympanostomy tubes (Group 2)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Adenoidectomy (Group 3)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Adenoidectomy and placement of tympanostomy tubes (Group 4)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Groups 2, 3, and 4
Number of subjects: 578

Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Group 4
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Adenoidectomy plus bilateral myringotomy
Number of subjects: 578
Study: 12629094

Group type: EXPERIMENTAL
Intervention: Group A: 4 IU/m².d (approximately 0.045 mg/kg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B: first year 4 IU/m².d; thereafter 6 IU/m².d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C: first year 4 IU/m².d; second year 6 IU/m².d; thereafter 8 IU/m².d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group A vs Group B
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group A vs Group C
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group B vs Group C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: After starting estrogen treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 60
Study: 29625440

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Aflibercept, Bevacizumab, Ranibizumab
Number of subjects: 660
Study: 27543470

Group type: EXPERIMENTAL
Intervention: Early direct current cardioversion (DCCV) and oral Amiodarone for 6 weeks (Group 2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Successful balloon mitral valvotomy (PBMV) alone (Group 1)
Number of subjects: 35
Study: 24886701

Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22868212

Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg NMC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 12.5 μg/kg NMC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 50.0 μg/kg NMC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2.5 μg/kg GRP
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC + 20.0 μg/kg [d‐Lys(3)]‐GHRP‐6
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC + 20.0 μg/kg N‐GRP‐EE
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 20.0 μg/kg N‐GRP‐EE
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMB
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC in pre-weaned calves
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC in rats
Number of subjects: 13
Study: 21126666

Group type: EXPERIMENTAL
Intervention: Infusion of warm fluids at 37° C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Infusion of room temperature fluids
Number of subjects: 30
Study: 19079957

Group type: EXPERIMENTAL
Intervention: 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval
Number of subjects: 166

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 166
Study: 15690266

Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 60 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 10 mg to 60 mg
Number of subjects: 8
Study: 12901778

Group type: EXPERIMENTAL
Intervention: Mild Alzheimer's disease (n = 244)
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Questionable dementia (QD)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Non-demented elderly controls
Number of subjects: 1602
Study: 10485770

Group type: EXPERIMENTAL
Intervention: Xenon (43% at 0.6 MAC) and isoflurane (0.5% at 0.4 MAC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isoflurane (1.2%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nitrous oxide (63% at 0.6 MAC) and isoflurane (0.5%)
Number of subjects: 15
Study: 7573470

Group type: EXPERIMENTAL
Intervention: Inhalation of H2SO4 aerosol (1,000 microgram/m3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhalation of NaCl aerosol (control)
Number of subjects: 12
Study: 1949257

Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 7262013

Group type: EXPERIMENTAL
Intervention: Verbal stimuli (mono-syllabic words, either 'neutral' or 'emotional')
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tones (400 Hz)
Number of subjects: 8
Study: 31286921

Group type: EXPERIMENTAL
Intervention: Justa cookstove intervention
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (traditional wood-burning cookstove)
Number of subjects: 230
Study: 29016185

Group type: EXPERIMENTAL
Intervention: Autologous Protein Solution (APS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 46
Study: 26752690

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (BP) z-score
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Blood glucose control
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Non-HDL
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) z-score
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (CRP)
Number of subjects: 784
Study: 24706091

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Search AV+ (SAV+)
Number of subjects: 385
Study: 22709422

Group type: EXPERIMENTAL
Intervention: Educational programme for chronic skin diseases (12-week duration)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 50
Study: 19636555

Group type: EXPERIMENTAL
Intervention: Oral leucovorin (LV) at a single dose of 25 mg administered 4 hours before surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral leucovorin (LV) at a single dose of 25 mg administered 12 hours before surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral leucovorin (LV) at a single dose of 25 mg administered 18 hours before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no LV administration)
Number of subjects: 60
Study: 19022974

Group type: EXPERIMENTAL
Intervention: Maternal protein-energy supplementation during pregnancy
Number of subjects: 1270
Study: 15800692

Group type: EXPERIMENTAL
Intervention: Radiofrequency coagulation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 240
Study: 15265397

Group type: EXPERIMENTAL
Intervention: Submucosal injection of pirarubicin
Number of subjects: 68
Study: 10875855

Group type: EXPERIMENTAL
Intervention: Ganirelix
Number of subjects: 730

Group type: COMPARATOR
Intervention: Buserelin (control)
Number of subjects: 730
Study: 9289671

Group type: EXPERIMENTAL
Intervention: Vaginal estriol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ethinyl‐estradiol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bromhexine associated with gonadotropins
Number of subjects: 30
Study: 1553933

Group type: EXPERIMENTAL
Intervention: Colchicine treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study: 3158675

Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg/24 hours for 10 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 and 1.0 g/kg of body weight
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 12
Study: 30597039

Group type: EXPERIMENTAL
Intervention: Circulating vitamin D concentrations (25(OH)D)
Number of subjects: 73769
Study: 29747432

Group type: EXPERIMENTAL
Intervention: Mangosteen extract with behavioral therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Behavioral therapy alone
Number of subjects: 22
Study: 27174904

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14171

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14171
Study: 24885585

Group type: EXPERIMENTAL
Intervention: 20 hours of intensive attention training by Attention Process Training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard, activity based training
Number of subjects: 120
Study: 22753219

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study: 20225393

Group type: EXPERIMENTAL
Intervention: ChAglyCD3
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18398592

Group type: EXPERIMENTAL
Intervention: Surrogate endpoint trials
Number of subjects: 0
Study: 15993231

Group type: EXPERIMENTAL
Intervention: Chloramphenicol eye drops
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 326
Study: 12814445

Group type: EXPERIMENTAL
Intervention: Low dose insulin (6 pmol min-1) + C-peptide (2-60 pmol min-1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High dose insulin (30 pmol min-1) + C-peptide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: C-peptide (during low dose insulin)
Number of subjects: 11
Study: 9808805

Group type: EXPERIMENTAL
Intervention: Profile group
Number of subjects: 958
Study: 7482389

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data collection for the INDANA project
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Main analysis of the INDANA project
Number of subjects: 0
Study: 2568765

Group type: EXPERIMENTAL
Intervention: Lofexidine (L)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study: 23018

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 0
Study: 30011318

Group type: EXPERIMENTAL
Intervention: Maternal milk supplementation (MMS) with a breastfeeding support program
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 204
Study: 27295488

Group type: EXPERIMENTAL
Intervention: Ball-kicking balance-perturbation training (BPT); single 30-minute session
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CG); no intervention
Number of subjects: 44
Study: 24786979

Group type: EXPERIMENTAL
Intervention: High left ventricular pacing threshold (LVPT) >1.8 V
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Lowest quartile LVPT
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: 1 volt increase in LVPT
Number of subjects: 975
Study: 22566414

Group type: EXPERIMENTAL
Intervention: Recall intervention for boys (RCT)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Usual care for boys (Control)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Demonstration study for girls
Number of subjects: 529
Study: 20889523

Group type: EXPERIMENTAL
Intervention: High-dose vitamins C and E (1000 mg vitamin C and 400 IU RRR α-tocopherol daily)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 18473176

Group type: EXPERIMENTAL
Intervention: Water (200 ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 12
Study: 15785901

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Diathermy excision
Number of subjects: 31
Study: 11918761

Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered PD solution (34 mmol/L, pH 7.4)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lactate-buffered PD solution (35 mmol/L, pH 5.5)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both bicarbonate and lactate buffered PD solutions
Number of subjects: 25
Study: 9972755

Group type: EXPERIMENTAL
Intervention: Cephalad-oriented Tuohy needle bevel
Number of subjects: 500

Group type: COMPARATOR
Intervention: Lateral-oriented Tuohy needle bevel
Number of subjects: 500
Study: 7762389

Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray once daily at night
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2221729

Group type: EXPERIMENTAL
Intervention: Trimetazidine (3 tablets daily for one month)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 342043

Group type: EXPERIMENTAL
Intervention: Topical ampicillin (1 g applied to the wound)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Wound irrigation with 1% cetyl trimethyl ammonium bromide (Savlon)
Number of subjects: 374
Study: 6196515

Group type: EXPERIMENTAL
Intervention: High-dose neuraminidase-treated allogeneic blasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific monoclonal antibodies or autologous cytotoxic T-cells
Number of subjects: 0
Study: 31305950

Group type: EXPERIMENTAL
Intervention: Mindfulness activity (1-minute duration)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Mindfulness activity
Number of subjects: 164
Study: 29806411

Group type: EXPERIMENTAL
Intervention: Self‐made nickel‐titanium shape memory alloy stepped plate (group A)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Calcaneal plate (group B)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cannulated compression screws (group C)
Number of subjects: 6
Study: 26802011

Group type: EXPERIMENTAL
Intervention: Patient-centered, tablet computer-based self-monitoring system
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional self-monitoring method
Number of subjects: 63
Study: 25503160

Group type: EXPERIMENTAL
Intervention: Polaprezinc in sodium alginate suspension (P‐AG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Azulene gargle (control)
Number of subjects: 36
Study: 22150876

Group type: EXPERIMENTAL
Intervention: Test group (TG): grafted using hydroxyapatite
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG): left to heal without grafting
Number of subjects: 20
Study: 20854207

Group type: EXPERIMENTAL
Intervention: Dapivirine gel (0.001%, 0.005%, or 0.02%) once daily on Days 1 and 10 and twice daily on Days 2-9
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dapivirine gel (0.001%, 0.005%, or 0.02%)
Number of subjects: 18
Study: 17460126

Group type: EXPERIMENTAL
Intervention: Computerized alert tool for pharmacists
Number of subjects: 11100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11100
Study: 16039775

Group type: EXPERIMENTAL
Intervention: 4.8 F stent
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 6 F stent
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (lower urinary symptoms from other causes)
Number of subjects: 34
Study: 11950252

Group type: EXPERIMENTAL
Intervention: Valdecoxib 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen 500 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib 5 mg and 10 mg
Number of subjects: 0
Study: 9709329

Group type: EXPERIMENTAL
Intervention: Padded trial
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unpadded trial
Number of subjects: 39
Study: 8133413

Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sterile colored water control
Number of subjects: 50
Study: 2803090

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1023955

Group type: EXPERIMENTAL
Intervention: Diazepam in glycoferol-alcohol-benzoic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam in cremophor EL
Number of subjects: 0
Study: 31992266

Group type: EXPERIMENTAL
Intervention: Hybrid off-job crafting intervention including on-site training, individual off-job crafting plan, smartphone app usage, and reflection training.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 31662165

Group type: EXPERIMENTAL
Intervention: Peer-led group
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Adult-led group
Number of subjects: 109
Study: 28981592

Group type: EXPERIMENTAL
Intervention: Low SVV group
Number of subjects: 80
Study: 26014292

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (10:1 ratio with doxorubicin, cumulative dose of 100 to 360 mg/m2)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Doxorubicin without dexrazoxane
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 1008
Study: 23862400

Group type: EXPERIMENTAL
Intervention: Intranasal sodium hyaluronate 9 mg twice daily for 30 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intranasal sodium hyaluronate
Number of subjects: 36
Study: 21415611

Group type: EXPERIMENTAL
Intervention: Centralized telecare management augmented by automated symptom monitoring (ASM)
Number of subjects: 202
Study: 18579227

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin plus clopidogrel)
Number of subjects: 400
Study: 17875857

Group type: EXPERIMENTAL
Intervention: Patients with cancer in the head and neck region
Number of subjects: 10

Group type: COMPARATOR
Intervention: Community control subjects
Number of subjects: 10
Study: 15479288

Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 3983

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 3983
Study: 10716083

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (1 x 400 mg tablet in the morning and 1 placebo tablet in the evening for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clarithromycin (1 x 500 mg tablet in the morning and 1 x 500 mg tablet in the evening for 7 days)
Number of subjects: 12